Is ABUS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Imdusiran functional-cure program, with revenue (ttm) at ~$182M, almost all from Q1 2026 (~$246M) settlement-related revenue. The bear case rests on arbutus carries the full risk profile of a clinical-stage biotech: outside the one-time settlement it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Arbutus carries the full risk profile of a clinical-stage biotech: outside the one-time settlement it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Imdusiran functional-cure program. Imdusiran, an RNAi therapeutic that suppresses HBV antigens, is Arbutus's lead asset and the core of the thesis.

Arbutus carries the full risk profile of a clinical-stage biotech: outside the one-time settlement it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. Analysts expect a loss of about $0.11 per share in 2027 once settlement income drops out. Curing chronic hepatitis B is scientifically hard, and functional-cure results seen in small Phase 2a groups may not hold up in larger, later-stage trials, which would sharply reduce the stock's value. The candidates still face years of development, regulatory uncertainty, and competition from other companies pursuing HBV cures. The contingent portion of the Moderna settlement is tied to an appellate ruling that may not be received in full, the Pfizer and BioNTech suits may not succeed, and after spending $230 million on the tender the remaining cash must stretch further. The stock fell below the $5.00 tender price after the offer closed, and biotech shares can move sharply on single data readouts. Investors should treat ABUS as a high-risk, potentially high-reward position rather than a stable holding.

Arbutus Biopharma is a clinical-stage biopharmaceutical company that leverages deep virology expertise to develop novel therapeutics aimed at a functional cure for chronic hepatiti

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Imdusiran functional-cure program) stalling in the reported numbers rather than in the narrative, the risk above (arbutus carries the full risk profile of a clinical-stage biotech: outside the one-time settlement it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice; Walnut is not an investment adviser. The bull case is promising imdusiran functional-cure data, FDA Fast Track designation, a 23% smaller share count after the 2026 tender, and possible further patent proceeds. The bear case is the ordinary high risk of an unprofitable clinical-stage biotech whose value hinges on trial results that can fail, a smaller cash cushion after the buyback, and uncertainty over the contingent settlement portion. Treat it as high-risk and verify current figures first.

Arbutus is a clinical-stage biotech developing therapies aimed at a functional cure for chronic hepatitis B. Its lead candidate, imdusiran, is an RNAi (RNA interference) drug that suppresses hepatitis B antigens, studied in combination with other agents. A second candidate, AB-101, is an oral PD-L1 inhibitor meant to reawaken the immune response against the virus. It has no approved products generating meaningful revenue yet.

Arbutus and its licensee Genevant reached a $2.25 billion global settlement with Moderna resolving patent litigation over lipid-nanoparticle delivery technology used in COVID-19 vaccines. The structure includes a large upfront noncontingent payment plus a further amount contingent on an appellate ruling. Arbutus recorded about $246 million of revenue in Q1 2026, and in October 2026 it used $230 million to repurchase shares through a tender offer.